Related Experiment Video
Updated: Jul 16, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial Involvement
Anna Burban1,2, Szymon Pucyło1, Aleksandra Sikora1
1First Department of Cardiology, Medical University of Warsaw, ul. Banacha 1A, 02-097 Warszawa, Poland.
Insights
Hypertrophic cardiomyopathy (HCM) and related genetic cardiomyopathies cause heart failure through left ventricular thickening. Research explores pharmacological and gene therapies, with genetic approaches showing promise but requiring further safety and efficacy studies.
Area of Science:
- Cardiology
- Genetics
- Pharmacology
Background:
- Cardiomyopathies are a significant cause of heart failure.
- Hypertrophic cardiomyopathy (HCM) is the most prevalent type, marked by left ventricular hypertrophy.
- Other genetic cardiomyopathies with myocardial hypertrophy include Fabry, Pompe, and Danon diseases.
Purpose of the Study:
- To review the genetics and pathogenesis of HCM and related hypertrophic cardiomyopathies.
- To summarize current and emerging treatment strategies.
- To highlight the potential of gene therapies for these conditions.
Main Methods:
- Review of existing literature on hypertrophic cardiomyopathies.
- Analysis of genetic and pathogenetic mechanisms.
- Evaluation of pharmacological and gene-based therapeutic approaches.
Main Results:
- Detailed description of the genetic underpinnings and disease progression in HCM, Fabry, Pompe, and Danon diseases.
- Overview of current treatments, including pharmacological interventions.
- Exploration of gene therapy as a potential future treatment modality.
Conclusions:
- Genetic cardiomyopathies, particularly HCM, require comprehensive understanding and treatment strategies.
- Gene therapies represent a promising avenue for treating these diseases.
- Further research is essential to validate the efficacy and safety of genetic treatments.
Abstract:
One of the main causes of heart failure is cardiomyopathies. Among them, the most common is hypertrophic cardiomyopathy (HCM), characterized by thickening of the left ventricular muscle. This article focuses on HCM and other cardiomyopathies with myocardial hypertrophy, including Fabry disease, Pompe disease, and Danon disease. The genetics and pathogenesis of these diseases are described, as well as current and experimental treatment options, such as pharmacological intervention and the potential of gene therapies. Although genetic approaches are promising and have the potential to become the best treatments for these diseases, further research is needed to evaluate their efficacy and safety. This article describes current knowledge and advances in the treatment of the aforementioned cardiomyopathies.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Myocarditis I: Introduction

